Realm Therapeutics PLC Presentation at 2017 Marcum Microcap Conference

TIDMRLM

Realm Therapeutics PLC

14 June 2017

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

Realm Therapeutics to present at the 2017 Marcum Microcap Conference

14 June 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting on Friday, June 16 at 11:30 EST, at the Marcum Microcap Conference at the Grand Hyatt Hotel in New York City.

Mr. Martin will review the Company's two drug development programs - PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis. Realm recently announced that the US Food and Drug Administration (FDA) has permitted the Company's Investigational New Drug (IND) application to proceed into Phase II clinical trials with its lead drug candidate PR022, and that it is on track to submit an IND for PR013 in Q3.

An updated corporate presentation will be available on the Company's website, www.realmtx.com, later today.

Enquiries:

 
                                         [phone] 
 Realm Therapeutics plc                   1000 
 Alex Martin, Chief Executive Officer 
 Marella Thorell, Chief Financial 
  Officer and Chief Operating Officer 
 
                                         [phone] 
 FTI Consulting                           1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser and       [phone] 
  Broker)                                 3000 
 Aubrey Powell / Lauren Kettle 
 

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.

Forward looking statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAQZLBFDQFBBBD

(END) Dow Jones Newswires

June 14, 2017 02:09 ET (06:09 GMT)